



3-305 Industrial Parkway South
Aurora, Ontario, Canada, L4G 6X7
Phone: (905) 841-2300
Fax: (905) 841-2244
Web: www.helixbiopharma.com

February 10, 2013
NEWS RELEASE

HELIX BIOPHARMA ANNOUNCES DIRECTOR RESIGNATION

(Aurora, Ontario) - Helix BioPharma Corp. (TSX, FSE: "HBP"), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced that on Friday, February 8, 2013 John A. Rogers has voluntarily resigned from Helix's board of directors.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Investor Relations:

Helix BioPharma Corp.

Tel: 905 841-2300

Email: ir@helixbiopharma.com
